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Abstract In order to determine whether the D2 and D3 
dopamine receptors may have a role in prenatal development, 
we have studied the mRNA expression and distribution of these 
receptors during murine embryonic development. Using RT-PCR 
on RNA from embryos taken at progressive stages of develop- 
ment, we have shown that the D3 receptor is expressed 
significantly earlier than the D 2 receptor, being detectable at 
day 9.5 post-conception (p.c.), compared with day 13.5 p.c. for 
the D2 subtype. We have also examined the mRNA distribution 
of the two receptors by whole mount in situ hybridisation. In 
agreement with the PCR assays, the D3 receptor was expressed 
cartier than the D2 sybtype. D3 receptor transcripts were first 
detected at day 9.5 p.c. in the ventral aspect of the anterior 
neural tube, whereas D2 receptor transcripts first appeared a day 
later. By day 10.5-11.5 p.c. both D 3 and D2 receptor transcripts 
were present in the developing forebrain, and later also in the 
branchial arches and along the prospective vertebral column. The 
early appearance of the D3 subtype in murine development and 
its predominance over the D2 subtype suggest that the D 3 
receptor may have a functional role in prenatal development. 
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1. Introduction 
The existence of multiple dopamine receptors was for many 
years postulated to underlie the complex behavioural and bio- 
chemical properties associated with dopaminergic neutrotrans- 
mission and dopamine receptor activation [1]. The identification 
and cloning of a number of dopamine receptor genes in the last 
few years has enabled amore detailed analysis of the functional 
roles played by the respective dopamine receptors than was pre- 
viously possible. Two categories of dopamine receptor are cur- 
rently recognised, termed D1 and D21, the latter in particular 
being associated with a number of neuropathological condi- 
tions (reviewed in [2]). While it is generally accepted that the 
cloned D2, D3 and D4 subtypes are of the D2 type, their 
differential roles in brain function remain to be determined 
[3,4]. A further level of diversity is found in the D2 subclass 
by the presence of alternative splicing in the D2 and D3 sub- 
types, generating long and short isoforms of each receptor, 
termed D2L, D2s, D3L and D3s [5-8], but the significance of 
alternative splicing to receptor function is still not clear. 
*Corresponding author. Fax: (972) (8) 9344141. 
1To avoid confusion, D2 shall be used to signify the subclass of D2- 
type receptors, defined by pharmacological and biochemical charac- 
teristics at the protein level, and a subscript shall be used to represent 
the cloned receptor subtypes, e.g. D2, D3 and D4. 
Studies examining the expression of D2-type receptors have 
shown that in the adult brain, the three subtypes exhibit dis- 
tinct but overlapping distribution. The D2 subtype is the most 
abundant of the three, being expressed most highly in the 
striatum and olfactory tubercle, and showing higher mRNA 
levels than either the D3 or D4 subtypes in all tissues where 
they are co-expressed. The D3 and D4 receptors are most 
highly expressed in limbic tissue [6,9,10], the D3 sybtype being 
found as both an autoreceptor and a post-synaptic receptor. 
The expression of dopamine receptors in pre- and post-na- 
tal development has previously been studied using autoradio- 
graphy and radioligand binding on embryonic rat brain slices 
[11,12]. These have shown D2-type receptors to be expressed 
before the formation of synaptic onnections in cortical and 
subcortical regions, but concomitantly with the expression of 
tyrosine hydroxylase, which serves as a marker for the pre- 
sence of the neurotransmitter. This approach, however, ob- 
serves the receptors at the protein level, and does not permit 
distinction between the different receptor subtypes or their 
alternatively spliced isoforms, which are all capable of binding 
the ligands used. Sutidies on whole brains from rat embryos 
have employed PCR to examine the expression of D2-type 
receptors, and have shown the D2 receptor to be present at 
rat embryonic day 14 [13] and the D3 receptor at rat embryo- 
nic day 11 [14], but did not examine the distribution of these 
receptors in the embryos. 
The use of foetal implants for the treatment of neurodegen- 
erative disorders uch as Parkinson's disease, has created sig- 
nificant interest into the distribution and function of dopa- 
mine receptors in embryonic tissue. In particular, the isolation 
of a number of different dopamine receptor subtypes has gen- 
erated a need to understand the respective roles these subtypes 
may play in the developing embryo. In this study, we have 
used PCR analysis and in situ hybridisation to examine and 
compare the expression and distribution of the D2 and Dz 
receptors in murine prenatal development. We have found 
that the D~ subtype is expressed significantly earlier than 
the D2 subtype, and suggest that at early stages of embryonic 
development it may represent the dominant D2-type receptor. 
2. Materials and methods 
2.1. Materials 
All molecular biology reagents, unless tated otherwise, were pur- 
chased from Boehringer Mannheim (Mannheim, Germany). PCR on 
cDNA was performed using Taq polymerase, Promega. Oligonucleo- 
tides and PCR primers were prepared by the laboratory of oligonu- 
cleotide synthesis. [7-32p]dATP (3000 Ci/mmol) and [35S]UTP (>1000 
Ci/mmol) were purchased from Amersham (Aylesbury, England), and 
nitrocellulose membranes were purchased from Schleicher and 
Schuell, GmbH (Dassel, Germany). All other reagents, unless tated 
otherwise, were purchased from Sigma Chemical Co. (St. Louis, MO). 
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2.2. RT-PCR and Southern analysis 
For RNA extraction, embryos were isolated and frozen immedi- 
ately in liquid nitrogen. Total RNA was prepared from whole em- 
bryos using the guanidium thiocyanate-caesium chloride method [15]. 
cDNA was prepared and PCR performed essentially as described 
previously [6]. Briefly, 15 ~tg total RNA was used for the generation 
of cDNA using oligo dT (New England Biolabs) and AMV Reverse 
Transcriptase (Promega), and the resulting cDNA was resuspended in 
20 ~tl; 5 ~tl of this was taken for amplification by PCR with either D2- 
specific (5'-CCTTCACCATCTCTTGC-3' and 5'-CCTTCTGCT- 
GGGAGAGC-Y) or Da-specific primers (5'-CCGTTGCTGAGTTT- 
TCGAACC-3' and 5'-CCAGGTTTCTGTCAGATGCC-3'). 35 ~tl of 
PCR products were electrophoresed on 1.2% agarose gels and trans- 
ferred to nitrocellulose membranes (Schleicher & Schuell). Hybridisa- 
tion was performed with D2-specific (5'-TGACAGTCCTGC- 
CAAACC-Y) and Da-specific (5'-CGGAACTCCTTGAGCCCCAC- 
CATGGCACCCAAGC-Y) oligonucleotide probes, end-labeUed with 
[y-32P]ATP and T4 polynucleotide kinase, by standard procedures 
[16]. 
2.3. Preparation of probes for in situ hybridisation 
D2- and Da-specific cDNA probes as detailed in section 3 were 
subcloned into the vector pBluescript and linearised using Asp-718 
and XbaI respectively, cRNA probes were generated by in vitro tran- 
scription using T7 and T3 RNA polymerase for the D2 and Da re- 
ceptors respectively, including 10 mM digoxin-UTP (DIG-UTP) for 
whole mount in situ hybridisation and [35S]UTP for paraffin section in 
situ hybridisation. 
2.4. Whole mount in situ hybridisation 
Whole mount in situ hybridisation was performed essentially ac- 
cording to Conlon and Herrmann [17], with minor modifications. 
Briefly, embryos were isolated and immediately fixed for 2 h in fresh 
4% paraformaldehyde (PFA) and bleached in H20~/methanol. Fol- 
lowing rehydration, embryos were treated with 20 lag/ml proteinase K,
rinsed twice in 2 mpdml glycine, refixed for 20 rain in 0.2% glutaral- 
dehyde/4% PFA/PBS, and treated for 20 min in sodium in sodium 
borohydride. Embryos were then prehybridised for 1 h at 63°C in 
hybridisation buffer (50% formamide, 0.75 M NaC1, l xPE (10 mM 
PIPES pH 6.8, 1 mM EDTA), 100/.tg/ml tRNA, 0.05% heparin, 0.1% 
BSA and 1% SDS), before hybridisation overnight at 63°C in the 
same solution containing 0.5-2 ~tg/ml DIG-labelled probe. Embryos 
were washed prior to digestion with 100/.tg/ml RNase A and 100 U/ml 
RNase T1 for 60 rain at 37°C and were then further washed prior to 
incubation at room temperature in 2% levamisole in TBST (20 mM 
Tris, 140 mM NaCI, 2.7 mM KC1, 0.1% Tween 20), containing 10% 
heat-inactivated goat serum. The secondary antibody (anti-digoxigen- 
in-AP, [alkaline phosphatase] Fab fragments [Boehringer Mannheim]) 
was diluted 1:5000 and preabsorbed with 2 mM levamisole, 1% heat- 
inactivated goat serum and heat inactivated embryo powder, in TBST, 
for 30 min at 4°C, prior to incubating overnight with the embryos at 
4°C. Embryos were then extensively washed in 2 mM levamisole/ 
TBST, and then in 2 mM levamisole inNTMT (100 mM NaC1, 100 
mM Tris, pH 9.5, 50 mM MgC12, 0.1% Tween 20), before developing 
the colour reaction with nitroblue tetrazolium salt (NBT) and 5-bro- 
mo-4-chloro-3-indolyl phosphate, toluidine salt (BCIP) (Boehringer 
Mannheim). 
2.5. Paraffin section in situ hybridisation 
Paraffin section in situ hybridisation was performed according to 
Wilkinson and Green (1990) [18], using cRNA probes for the D2 and 
D3 dopamine receptors labelled with [a~S]UTP. 
3. Results 
3.1. The D3 receptor appears at an earlier developmental stage 
than the D2 receptor 
In order to examine whether the D2 and D3 receptors are 
expressed uring embryonic development, PCR was used to 
amplify fragments of the D2 and D3 receptors from murine 
embryos at progressive stages of prenatal development. Total 
RNA was prepared from murine embryos of day 9.5 to day 
17.5 post-conception (p.c.), and was used for the generation of
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Fig. 1. Southern analysis of PCR performed on embryonic RNA 
taken from progressive stages of development. Hybridisation of elec- 
trophoresed PCR products was performed with D2-specific (top) 
and D3-specific (bottom) primers as described in section 2. 
cDNA. The cDNA templates for each developmental stage 
were used in PCR with D2-specific or D3-specific primers. 
These primers were based on sequences in each receptor's 
third cytoplasmic loop and were designed to amplify frag- 
ments of both short and long receptor isoforms which could 
be distinguished by agarose gel electrophoresis. Control PCR 
reactions using no template DNA produced no signal for 
either the D2 or the D3 receptors (data not shown). Fig. 1 
shows that the D2 receptor transcripts first appear at day 13.5 
p.c., and show a gradual increase in the subsequent days. The 
D3 receptor, by contrast, is detectable as early as day 9.5 p.c., 
and its mRNA levels peak at day 12.5 p.c. The long and short 
isoforms of the D3 receptor show some slight variation in the 
pattern of their appearance, unlike those of the D2 receptor 
which show an identical pattern. This differs quite markedly 
from the situation in the adult brain, in which the D2 receptor 
is generally expressed at much higher levels than the D3 sub- 
type, and gives rise to the notion that the D3 receptor subtype 
may serve as the dominant D2-type receptor in early develop- 
mental stages. 
3.2. Distribution of  D2 and D3 receptor transcripts 
In order to examine the localisation of D2 and D3 receptor 
transcripts in murine embryos, DIG-labelled D2-specific and 
D3-specific RNA probes were used in whole mount hybridi- 
sation. This technique permits the entire embryo rather than 
sections to be visualised, and involves detection by alkaline 
phosphatase-linked anti-DIG antibodies and generation of a 
colour signal. 
No signal could be detected in 8.5 day embryos for either 
D3 receptors (Fig. 2) or D2 receptors (data not shown). At 
day 9.5 p.c. however D3 receptor mRNA was present in or 
around the optic vesicle and at the ventral aspect of the dien- 
cephalon, whereas the D2 receptor was still undetectable. The 
high specificity of the signal in whole mount in situ hybridiza- 
tion is documented by the low background in the 9.5 day old 
embryo hybridized with the D2 probe. As shown in Fig. 3, at 
day 10.5 p.c., the D3 receptor mRNA is present in the otic pit, 
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and in the mid and forebrain, including the telencephalic ves- 
icles. A sharp boundary of D3 receptor expression is demon- 
strated along the border of the mid-brain and hind-brain, and 
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Fig. 2. Whole mount in situ hybridisation of 8.5 day and 9.5 day 
p.c. mouse embryos using D2- and Da-specific probes as indicated. 
The first appearance of Da receptor mRNA can be seen at day 9.5, 
compared with the absence of D2 receptor at this stage. Specific sig- 
nals for the D3 receptor can be seen around the optic vesicle, and 
in the ventral aspect of the diencephalon. Abbreviations: fb, fore- 
brain; hb, hind-brain; mb, mid-brain; op, otic pit; ov, optic vesicle. 
or -  
signals begin to be detectable in the branchial arches and 
along the prospective vertebral column (Fig. 3, left). At the 
same developmental ge similar, but considerably weaker D2 
receptor expression becomes detectable (Fig. 3, right). This 
supports the results from PCR shown in Fig. 1, which indicate 
that the D3 receptor is expressed prior to the D2 receptor 
during murine embryonic development. 
To obtain additional evidence of the distribution of D2 and 
D3 receptor transcripts and to assess the identity of the cell 
layer where the receptor is expressed, histological in situ hy- 
bridisation was performed on paraffin sections of 11.5 day 
embryos, using the same cRNA probes as those above, la- 
belled with [3~S]UTP. Fig. 4 demonstrates that both Dz and 
D3 receptor transcripts are present at this age along the ex- 
ternal marginal ayer of the telencephalic vesicles and, to a 
lesser degree, the hind-brain and spinal cord, also demonstrat- 
ing that by day 11.5 p.c., both D3 and D2 receptor transcripts 
are present in the developing central nervous system. 
4. Discussion 
In this study, we have examined the expression of the D2 
and D 3 dopamine receptor subtypes in murine embryonic de- 
velopment, and have found that the D3 receptor appears to be 
the dominant D2-type receptor in early stages of prenatal 
development. The appearance of the D3 receptor mRNA prior 
to that of the D2 receptor is evident from experiments de- 
scribed here using both PCR and in situ hybridisation. This 
earlier expression of the D3 receptor appears also to occur in 
the rat, in which mRNA encoding the D3 receptor is ex- 
10.5 days 
10.5 days 
D3 D2 
Fig. 3. Whole mount in situ hybridisation of 10.5 day p.c. mouse embryos using D2- and Da-specific probes as indicated. Increasing distribu- 
tion of the D3 receptor signal can be seen in the optic pit (top, left) and telencephalic vesicles (bottom, left). First appearance of the D2 recep- 
tor occurs at day 10.5 in the otic pit (bottom, right). 10.5 day embryos are shown from more than one angle. Abbreviations: op, otic pit; tv, 
telencet~halic vesicle. 
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Fig. 4. Paraffin section in situ hybridisation 11.5 day p.c. mouse em- 
bryos using D3-specific (top) or De-specific (bottom) antisense RNA 
probes, showing the presence of D2 and D3 receptor mRNA at day 
11.5 in the developing nervous system. Abbreviations: de, dience- 
phalon; hb, hind-brain; tv, telencephalic vesicle. 
pressed, albeit at very low levels, at rat embryonic day 11 [19], 
while the earliest reported appearance of the D2 subtype is at 
rat embryonic day 14 [20]. Comparison of the developmental 
stages in the rat and mouse shows that rat day 11 p.c. is 
equivalent o murine days 9.5-10 p.c., and rat day 14 p.c. 
relates approximately to murine days 12.5-13.5 p.c. Our 
data therefore place the first detectable expression of the mur- 
ine D2 receptor to an earlier stage than that reported for the 
rat by Mack et al. [20]. High sensitivity of localization tech- 
niques, as compared to averaging approaches, and other tech- 
nical differences as well as the species difference may explain 
this discrepancy. 
Earlier studies using ligand-binding autoradiography de- 
monstrated the presence of De-type receptor protein in rat 
embryos at rat embryonic day 12 [12]. We were also able to 
detect he presence of Dr and Da receptor protein in murine 
embryos, using whole mount immunohistochemistry with sub- 
type-specific antibodies (data not shown), supporting the stud- 
ies in the rat. Interestingly, the radioligand binding studies in 
the rat showed that by rat embryonic day 15, the De-type 
receptors expressed uring this stage of prenatal development 
are functional and can operate signal transduction pathways. 
Using the technique of whole mount in situ hybridisation, 
we have been able to analyse the distribution of the receptor 
transcripts at early developmental stages, and have shown 
that although there is a temporal difference between the ex- 
pression of the D2 and D3 receptors, their patterns of distri- 
bution are quite similar. The presence of D2 receptor mRNA 
at earlier stages of development (day 10.5 p.c.) than was de- 
tected by PCR is most probably due to the fact that the D2 
receptor signal is very weak at this stage and may therefore 
not be sufficiently abundant for detection by PCR under the 
conditions used. The distribution of D3 receptor mRNA at 
early developmental stages is also highly restricted, appearing 
first in the optic and otic vesicles and in the diencephalon, 
which ultimately form the eye, ear and thalami, respectively. 
This expression pattern may indicate that dopaminergic recep- 
tors may be involved in the development of the porsencepha- 
lon and its derivatives the diencephalon the neuroretina nd 
optic nerve as well as the auditory apparatus. The presence of 
D2 and D3 receptor mRNA in the adult thalamus has pre- 
viously been shown using Northern analysis and in situ hy- 
bridisation [21,22]. 
It is worth noting that the areas richest in D2 and D3 
receptors in the murine embryo, the optic and otic vesicles, 
develop into structures, the eye and the ear, which do not 
belong to the central nervous system. Significantly, the pres- 
ence of D2-type receptors in the adult retina has been demon- 
strated in several species [14] and in the goldfish retina, De- 
type receptors are found to be coupled to the regulation of 
dopamine release [23], implying an autoreceptor role in this 
tissue. Given the previous characterisation f the D3 subtype 
as a possible autoreceptor [9], and the identification of D3 
receptor transcripts in the optic vesicle described here, it 
would be interesting to determine whether the D3 may have 
a role in the developing or adult eye, and if so, whether that 
role may involve an autoreceptor function. 
The results presented here indicate clearly that Dz receptor 
mRNA is expressed in murine embryonic development signif- 
icantly earlier than the D2 receptor, and demonstrate hat for 
both receptors, the long and short isoforms follow similar 
patterns of appearance. Although D2 receptor mRNA can 
be detected in early embryos using whole mount in situ hy- 
bridisation, the ability of PCR to amplify D3 receptor tran- 
scripts under conditions where the Dr receptor was not am- 
plified, suggests that the D3 receptor is more abundant han 
the D2 receptor at these stages. Thus it appears that at early 
stages of development, the D3 receptor may be the dominant 
De-type receptor, in contrast o the adult, in which the De 
receptor is expressed at considerably higher levels in all tissues 
where the two receptors are co-located. Whether the Dr and 
D3 receptors act as functional receptors or influence the de- 
velopmental process in the early murine embryo remains to be 
determined. It is worth noting that these receptors can regu- 
late neuronal outgrowth when expressed in a clonal mesence- 
phalic cell line (MN9D) [24], suggesting that they are capable 
of modulating neuronal morphogenesis. It will be interesting 
to determine whether the D3 receptor indeed functions as the 
principal De-type receptor in early murine embryos, and 
whether these receptors may be involved in the process of 
prenatal development. 
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